On January 16, 2015, at the age of 33, singer Yao Beina passed away at Peking University Shenzhen Hospital due to a recurrence of breast cancer. A rising star, a young and vigorous life, came to an abrupt end because of the word “breast cancer”. Yao Beina passed away, leaving behind her unfinished musical dreams and people’s endless sighs. Along with the sighs, people cannot help but ask why the surgery failed to completely remove the breast cancer after Yao Beina had undergone a mastectomy after being diagnosed with breast cancer. What kind of defense should be built against breast cancer? Breast cancer has become one of the most rapidly increasing malignant tumors in recent years. According to the latest 2013 China Tumor Registry Annual Report, there are as many as 210,000 new cases of breast cancer in China every year, which has become the biggest killer threatening women’s health. In fact, the incidence of breast cancer in the urban population has been increasing year by year since the 1980s, and the trend of youth is significant. 169,000 new cases of breast cancer were reported in China in 2008, and it is expected that by 2030, the number of breast cancer cases in China will reach 234,000, an increase of 27.8%. There are many factors that lead to the occurrence of breast cancer, early menarche, older age of first pregnancy, not breastfeeding, high fat diet, and genetic factors are known to be the causative factors. In addition, the high work pressure, fast pace of life and irregular work and rest in modern times have increased the risk of breast cancer in women. In the battle against breast cancer, due to the difference in the level of public awareness, many patients have excessive fear and anxiety about the disease due to lack of knowledge, resulting in treatment “detours”, which not only causes unnecessary pain, but also affects the effectiveness of subsequent treatment. Some patients may even turn to the doctor in a hurry and believe in folk remedies, resulting in blind treatment and negative treatment, causing deterioration of the disease and causing great regret to their lives. Therefore, patients need to construct a strong psychological defense when encountering breast cancer. With the joint efforts of doctors, family and society, they should better understand the disease and actively receive standardized treatment to strive for the greatest possibility of cure and survival. Breast cancer is different depending on the type of breast cancer. Although the incidence of breast cancer has been on the rise in recent years, it is heartening to know that the chances of survival of breast cancer patients have been greatly improved. The improvement of survival rate is due to two reasons: firstly, with the popularization of breast cancer knowledge, more and more patients are able to achieve early detection and treatment; secondly, the advancement of treatment, breast cancer treatment is no longer only surgery, but also comprehensive treatment including radiotherapy, chemotherapy, endocrine therapy, targeted therapy and traditional Chinese medicine plays a vital role. Many patients wonder why their treatment methods are different from other patients when they are also suffering from breast cancer. Modern medical research has confirmed that breast cancer is not a single disease, but a disease composed of “multiple members”. The family of breast cancer is broadly divided into the following subtypes: Luminal A, Luminal B, HER-2 positive, and “basal cell-like carcinoma (triple negative)”, etc. Luminal A is the most numerous in the family, accounting for about 60% of the total; HER-2 positive accounts for 20% to 30%. Basal cell-like carcinoma (triple-negative) type accounts for 10%-17%. The characteristics of different subtypes of breast cancer vary. The ability of cancer cells to migrate to surrounding and distant tissues and organs is medically referred to as invasiveness and metastasis, and those with strong invasiveness and metastasis have a poorer prognosis. Among breast cancer families, Luminal A and B breast cancers are milder, especially Luminal A, which are less aggressive and metastatic, and have a relatively low risk of recurrence/metastasis after surgery; HER-2 positive type is “acute” and more dangerous, and these patients have a poor prognosis, are prone to metastasis and recurrence, and are often insensitive to conventional treatment. These patients have a poor prognosis, are prone to metastasis and recurrence, and are often insensitive to conventional treatment. Basal cell-like carcinoma (triple negative) is not only acute, but also “rampant”, prone to recurrence/metastasis, and prone to lung, liver, brain and other visceral metastases, and has the worst prognosis. In the actual treatment process, there are always patients who refuse or even give up the treatment due to incomplete knowledge about the standard treatment of breast cancer, thus losing their precious and only chance of survival. For breast cancer patients, there is no need to be overly panic, and they should not give up lightly. They should follow medical advice and actively receive standardized treatment, including effective post-operative systemic treatment, in order to maximize the chance of cure and survival. Since the sensitivity of different subtypes of breast cancer to different adjuvant treatments is very different, standardized treatment must be “targeted”. For example, Luminal A type is more sensitive to endocrine therapy, and patients with this type need endocrine therapy, which is usually based on tamoxifen with or without ovarian function suppression before menopause, and aromatase inhibitors after menopause, as well as chemotherapy or radiotherapy in combination with other clinicopathological features of patients. Patients with HER-2 positive breast cancer are more aggressive, prone to metastasis/recurrence, and insensitive to conventional treatments such as chemotherapy and endocrine therapy alone, and need to receive anti-HER-2 targeted therapy in combination with chemotherapy and/or endocrine therapy, usually using trastuzumab in the adjuvant phase; basal cell-like (triple negative) breast cancer is currently the only option for chemotherapy, usually using anthracycline and paclitaxel-based regimens. As can be seen, it is important to accurately detect molecular markers such as estrogen receptor, progesterone receptor and HER-2 in breast cancer cells, and then classify the members of breast cancer families. Therefore, patients need to actively cooperate with clinicians for standardized testing to achieve the most optimal treatment effect through individualized standardized treatment to improve survival chances and quality of life. Tips for Breast Screening With the increasing awareness of health, many women are aware of the significance of regular breast screening, but not everyone knows what kind of screening is suitable for them. In fact, women of different ages should choose different mammography screening methods. Mammography is now internationally recognized as the most effective means of breast screening. It is recommended that women start having mammograms once a year at age 40 and every one to two years after age 60. However, the accuracy of mammography in diagnosing breast disease can be affected by the denseness of the breast. Younger women often have dense shadows and a lack of contrast throughout the breast because of the dense glands and abundant fibrous tissue. Therefore, mammograms for women younger than 35 years of age are not as valuable as screening for women older than 35 years of age. Fibroadenomas, lobular tumors, cysts and lobular hyperplasia are more common in younger women than breast cancer. Ultrasound not only shows these breast diseases more clearly than mammograms, but also identifies most of these benign and malignant tumors. Therefore, for young women under the age of 35, breast ultrasound can be used as the preferred screening method.